Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2016 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Presents GALE-301/GALE-302 Phase 1b Data at the American College of Surgeons Clinical Congress 2016

SAN RAMON, Calif., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology...
October 10, 2016 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present NeuVax™ (nelipepimut-S) plus Trastuzumab Interim Safety Data at the European Society for Medical Oncology (ESMO) 2016 Congress

SAN RAMON, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology...
September 29, 2016 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present NeuVax™ (nelipepimut-S) Interim Safety Data at the European Society for Medical Oncology (ESMO) 2016 Congress

SAN RAMON, Calif., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and...
September 27, 2016 16:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Presents GALE-301 Folate Binding Protein Expression Data at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

SAN RAMON, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and...
September 20, 2016 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at the Sachs Associates 16th Annual Biotech in Europe Forum

SAN RAMON, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and...
September 14, 2016 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at the 2016 Aegis Growth Conference

SAN RAMON, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and...
September 13, 2016 09:50 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Presents Preclinical NeuVax™ (nelipepimut-S) Data in Ovarian and Pancreatic Cancer at the Progress in Vaccination Against Cancer (PIVAC) Conference

SAN RAMON, Calif., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and...
September 12, 2016 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan

SAN RAMON, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and...
September 09, 2016 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

SAN RAMON, Calif., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and...
August 09, 2016 16:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Reports Second Quarter 2016 Financial Results and Provides a Corporate Update

Advancing GALE-401 (Anagrelide CR) into a pivotal trial for the treatment of essential thrombocythemiaClosing NeuVax Phase 3 PRESENT trialNeuVax combination trials with trastuzumab continueWebcast...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right